EUVIMEDEUVIMED entdecken
Crossref

Discovery of Spiro[pyrrolidine-3,3′-oxindole] LXRβ Agonists for the Treatment of Osteoporosis

Hao Chen, Pei Hua, Dane Huang, Yuting Zhang, Huihao Zhou iD, Jun Xu iD, Qiong Gu iD

Journal of Medicinal Chemistry · 12.01.2023 · 66 (1) · 752-765

DOI: 10.1021/acs.jmedchem.2c01661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.12.2022. Verfasst von Hao Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Drug Discovery at School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Orphan Nuclear Receptors, Osteoporosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Guangdong Science and Technology Department, National Natural Science Foundation of China, Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoclasts have an additional demand for cholesterol compared to normal cells. Liver X receptors (LXRs) are famous for regulation of lipid and cholesterol metabolism. Therefore, we propose that the LXR β agonist can regulate the cholesterol balance in osteoclasts to inhibit osteoclast differentiation. Here, we designed and synthesized a novel LXRβ agonist by introduction of the privileged fragments from anti-osteoporosis agents to the spiro[pyrrolidine-3,3'-oxindole] scaffold which is a novel scaffold of LXR agonists in our previous research. As a result, seven LXRβ agonists inhibited osteoclastogenesis with IC50 values ranging from 0.078 to 0.36 μM. Especially, the most potent LXRβ agonist B9 significantly inhibited RANKL-induced osteoclast differentiation and bone resorption in vitro and in vivo. Furthermore, B9 selectively activated LXRβ to promote intracellular cholesterol exclusion in osteoclasts and reduce extracellular cholesterol uptake and thereby inhibited osteoclast production. This study provides a new strategy to develop LXRβ agonists for osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Nuclear ReceptorsOsteoporosisHumansOxindolesOsteoclastsLiver X ReceptorsPyrrolidinesCholesterol

Substanzen

Orphan Nuclear ReceptorsOxindolesLiver X ReceptorsPyrrolidinesCholesterol

Autor:innen und Institutionen

  • Research Center for Drug Discovery at School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.

ORCID-Profile: Huihao Zhou, Jun Xu, Qiong Gu

Förderung

  • Guangdong Science and Technology Department
  • National Natural Science Foundation of China
  • Guangdong Province

Zitieren

APA

Chen, H., Hua, P., Huang, D., Zhang, Y., Zhou, H., Xu, J., & Gu, Q. (2023). Discovery of Spiro[pyrrolidine-3,3′-oxindole] LXRβ Agonists for the Treatment of Osteoporosis. Journal of Medicinal Chemistry, 66(1), 752-765. https://doi.org/10.1021/acs.jmedchem.2c01661

Vancouver

Chen H, Hua P, Huang D, Zhang Y, Zhou H, Xu J, et al. Discovery of Spiro[pyrrolidine-3,3′-oxindole] LXRβ Agonists for the Treatment of Osteoporosis. Journal of Medicinal Chemistry. 2023;66(1):752-765. doi:10.1021/acs.jmedchem.2c01661

BibTeX
@article{Chen2023,
  author = {Chen, Hao and Hua, Pei and Huang, Dane and Zhang, Yuting and Zhou, Huihao and Xu, Jun and Gu, Qiong},
  title = {Discovery of Spiro[pyrrolidine-3,3′-oxindole] LXRβ Agonists for the Treatment of Osteoporosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {1},
  pages = {752--765},
  doi = {10.1021/acs.jmedchem.2c01661}
}
Kostenlos starten →